Inert Drug System for Blocking Off-Target Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug designs face challenges with low specificity, leading to increased dosages, toxic and side effects due to off-target binding, and reduced efficacy, particularly in treatments for diseases like cancer where drugs may bind to non-intended targets, causing unintended toxicity and ineffectiveness.
Innovation Solution
A biologically inert drug system is developed, comprising a targeting moiety and an inert moiety that does not have biological activity, which is used in conjunction with a biologically active drug to improve specificity by blocking or eliminating non-target binding sites, thereby reducing off-target effects and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a biologically active drug is used to treat tumors, then therapeutic effect is achieved, but off-target binding causes toxicity and side effects
Solution Approach 1:
The patent segments the drug system into two distinct components: a biologically active drug that provides therapeutic effect and a biologically inert drug that blocks off-target binding. This segmentation allows each component to perform its specific function independently, resolving the contradiction between achieving therapeutic effect and avoiding toxicity.
Solution Approach 2:
The biologically inert drug acts as an intermediary that binds to off-target sites and prevents the biologically active drug from binding to these non-intended targets. This intermediary component protects the active drug from causing off-target toxicity while maintaining its therapeutic function.
2Quantity of substance
If drug dosage is increased to overcome off-target binding, then more drug reaches target sites, but toxic and side effects increase
Solution Approach 1:
By dividing the drug system into active and inert components, the patent enables the inert component to absorb excess dosage that would otherwise bind to off-target sites. This allows higher total drug dosage to be administered without proportionally increasing toxicity, as the inert component protects the active component from off-target binding.
Solution Approach 2:
The biologically inert drug serves as a non-functional copy or analog of the biologically active drug, sharing similar binding properties but lacking therapeutic activity. This copy binds to off-target sites in place of the active drug, preventing the active drug from causing toxicity at higher dosages.
3Reliability
If a biologically active drug binds to non-target organs, then drug is consumed, but effectiveness at target organ is reduced
Solution Approach 1:
The biologically inert drug performs preliminary binding to off-target sites before the biologically active drug can bind there. This preliminary action prevents the active drug from being consumed by non-target binding, ensuring that more active drug remains available to bind to and treat the target organ.
Solution Approach 2:
The inert drug acts as an intermediary that intercepts the active drug's binding to off-target sites, preventing premature consumption of the active drug. This intermediary protection ensures that the active drug is preserved for its intended therapeutic function at the target organ.
4Reliability
If antibody drugs target HER2 for breast cancer treatment, then tumor effects are achieved, but cardiovascular toxicity occurs due to HER2 distribution in heart tissue
Solution Approach 1:
The patent segments the HER2-targeting system into an active antibody drug that treats breast cancer and an inert antibody drug that blocks HER2 binding in the heart. This segmentation allows differential protection: the inert component specifically protects against cardiovascular toxicity while the active component maintains tumor treatment efficacy.
Solution Approach 2:
The biologically inert HER2-targeting antibody serves as an intermediary that preferentially binds to HER2 in the heart tissue, protecting the active antibody from causing cardiovascular toxicity. This intermediary selectively shields the active drug from binding to cardiac HER2 while allowing continued binding to tumor HER2.
Data Source
Figure 1
Figure 2
Figure 3A~3F
AI summary
Provided is a drug system design method, comprising selecting a target moiety specifically binding to a target of interest, and connecting the target moiety to a biologically active moiety and/or connecting the target moiety to a biologically inert moiety. Also provided are a test kit, a drug kit or a pharmaceutical composition including a biologically inert drug comprising the target moiety and the biologically inert moiety and a biologically active drug comprising the target moiety and the biologically active moiety, wherein the biological inert drug and the biologically active drug target a same target. Also provided is a method for using the drugs or the pharmaceutical composition to treat diseases such as those related to ED-B.